Data from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
DOI:
10.1158/1078-0432.c.6532968.v1
Publication Date:
2023-04-01T05:57:26Z
AUTHORS (29)
ABSTRACT
<div>AbstractPurpose:<p>To explore the role of <i>NBN</i> as a pan-cancer susceptibility gene.</p>Experimental Design:<p>Matched germline and somatic DNA samples from 34,046 patients were sequenced using Memorial Sloan Kettering-Integrated Mutation Profiling Actionable Cancer Targets presumed pathogenic variants (PGV) identified. Allele-specific gene-centered analysis enrichment was conducted validation cohort 26,407 analyzed. Functional studies utilized cellular models with protein expression, MRN complex formation/localization, viability assessment following treatment γ-irradiation.</p>Results:<p>We identified 83 carriers 32 PGVs (0.25% studied series), 40% which (33/83) carried Slavic founder p.K219fs. The frequency varied across cancer types. Patients harboring demonstrated increased loss wild-type allele in their tumors [OR = 2.7; confidence interval (CI): 1.4–5.5; <i>P</i> 0.0024; pan-cancer], including lung pancreatic compared breast colorectal cancers. p.K219fs enriched all tumor types (OR 2.22; CI: 1.3–3.6; 0.0018). Gene-centered revealed cases controls European population 1.9; 1.3–2.7; 0.0004), finding confirmed replication 1.8; 1.2–2.6; 0.003). Two novel truncating variants, p.L19* p.N71fs, produced 45 kDa fragment generated by alternative translation initiation that maintained binding to MRE11. Cells expressing these fragments showed higher sensitivity γ-irradiation lower levels radiation-induced KAP1 phosphorylation.</p>Conclusions:<p>Burden analyses, biallelic inactivation, functional evidence support contributing broad spectrum. Further large series epistatic environmental interactions are warranted further define associations.</p></div>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....